



**RD Therapeutics and Rapid Dose Therapeutics Participate in the CEPI Global Pandemic Preparedness Summit and Support the #100DaysMission — the value of needle-free vaccination, such as the QuickStrip™, will be discussed.**

BURLINGTON, Ontario – March 8, 2022- Rapid Dose Therapeutics Corp. (“**RDT**” or the “**Company**”) (**CSE: DOSE**), a Canadian biotechnology company focused on health and wellness leveraging an innovative, proprietary oral delivery medication and nutraceutical platform, along with their UK and European partner **RD Therapeutics**, proudly supports the [#100DaysMission](#).

As an invited guest, Ailene Thiel, CEO, RD Therapeutics is participating in the March 7 & 8 Coalition for Epidemic Preparedness Innovations’ (CEPI) Global Pandemic Preparedness Summit. The Summit is bringing together world leaders from governments, international agencies, science and academia, industry, philanthropy, and civil society to continue the valuable work being done to meet global unmet medical needs and mobilize critical resources needed for CEPI’s \$3.5 billion pandemic plan to ensure a more equitable response for future pandemics.

Specifically, the Summit will explore how to respond to the next “Disease X” by making safe, effective vaccines (including needle-free solutions), therapeutics, and diagnostics within 100 days of the World Health Organization’s (WHO) identification of a new pathogen, and identifying how the world can boost its ability to scale up production of vaccines in the future. The #100DaysMission has recognized the need to compress vaccine development timelines in an effort to save lives and trillions of dollars of economic damage.

Together, RD Therapeutics and Rapid Dose Therapeutics are committed to enabling equitable access to vaccines through the development of a temperature and humidity-stable, oral (i.e. needle-free) delivery platform (QuickStrip™) for vaccines. The QuickStrip vaccine platform is expected to decrease time to market and increases geographic reach by eliminating costly and logistically complicated cold-chain transportation and storage requirements while reducing healthcare costs associated with vaccination programs by removing the need for medical professional administration.

**Ailene Thiel, CEO, RD Therapeutics**, said: “We are committed to enabling equitable access to vaccines. A very large part of the world is currently struggling to obtain and distribute needle-based therapies. Oral vaccination via the buccal or sublingual route can be achieved through self-administration, avoids the complex requirements for cold-chain storage and transportation, is non-invasive, and can be easily delivered to remote populations. As such, it is well positioned to address unmet medical needs in developing countries—a critical element in controlling or preventing a global pandemic.”



**Mark Upsdell, CEO Rapid Dose Therapeutics**, said: “Our QuickStrip technology is showing a great deal of promise in a number of critical health parameters including rapid onset and improved bioavailability. We are well into our business plans of marrying the technology of our strip with other already-existing pharmaceutical and vaccine products in an effort to eliminate many of the current barriers to global vaccination – needles, limited healthcare professional resources and cold chain. We are proud to be working with Ailene Thiel and her team as she introduces our technology to the world this week at the Pandemic Preparedness Summit.”

### **About RD Therapeutics**

Driven by science, technology and clinical evidence, RD Therapeutics was formed by a multidisciplinary team of industry experts with **global experience across the technology, pharmaceutical and nutraceutical industries**. The company’s professional trajectory has taught it the importance of being at the forefront of research and technological advances in product development to bring to market a unique range of products that will help to create a society in which health and wellness as a way of life is within the reach of all.

[www.rdtherapeutics.com](http://www.rdtherapeutics.com)

### **About Rapid Dose Therapeutics Corp.**

Rapid Dose Therapeutics is a Canadian biotechnology company focused on Health and Wellness is revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.

[www.rapid-dose.com](http://www.rapid-dose.com)

### **For more information:**

#### **Canada/United States**

Dara Willis

[dara@dwcomm.ca](mailto:dara@dwcomm.ca)

416-836-9272

#### **United Kingdom/Europe**

Stephanie Gillespie

[stephanie@rdtherapeutics.com](mailto:stephanie@rdtherapeutics.com)

+ 1 242 815 9810

### **CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:**

*Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or*



*the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.*